Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-06-2011 | Short Communication

¹⁸F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study

Authors: Erwin M. Wiegman, Jan Pruim, Jan F. Ubbels, Harry J. M. Groen, Johannes A. Langendijk, Joachim Widder

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2011

Abstract

Purpose

¹⁸F-Fluorodeoxyglucose positron emission tomography (FDG PET) has been used to assess metabolic response several months after stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer. However, whether a metabolic response can be observed already during treatment and thus can be used to predict treatment outcome is undetermined.

Methods

Ten medically inoperable patients with FDG PET-positive lung tumours were included. SBRT consisted of three fractions of 20 Gy delivered at the 80% isodose at days 1, 6 and 11. FDG PET was performed before, on day 6 immediately prior to administration of the second fraction of SBRT and 12 weeks after completion of SBRT. Tumour metabolism was assessed semi-quantitatively using the maximum standardized uptake value (SUV_max) and SUV_70%.

Results

After the first fraction, median SUV_max increased from 6.7 to 8.1 (p = 0.07) and median SUV_70% increased from 5.7 to 7.1 (p = 0.05). At 12 weeks, both median SUV_max and median SUV_70% decreased by 63% to 3.1 (p = 0.008) and to 2.5 (p = 0.008), respectively.

Conclusion

SUV increased during treatment, possibly due to radiation-induced inflammation. Therefore, it is unlikely that ¹⁸F-FDG PET during SBRT will predict treatment success.

Reif MS, Socinski MA, Rivera MP. Evidence-based medicine in the treatment of non-small-cell lung cancer. Clin Chest Med 2000;21(1):107–20. ix.PubMedCrossRef

Lagerwaard FJ, Senan S, van Meerbeeck JP, Graveland WJ, Rotterdam Oncological Thoracic Study Group. Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer? Radiother Oncol 2002;63(2):151–7.PubMedCrossRef

Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010;94(1):1–11.PubMedCrossRef

Ishimori T, Saga T, Nagata Y, Nakamoto Y, Higashi T, Mamede M, et al. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med 2004;18(8):669–74.PubMedCrossRef

Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007;56(2):229–34.PubMedCrossRef

Henderson MA, Hoopes DJ, Fletcher JW, Lin PF, Tann M, Yiannoutsos CT, et al. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010;76(3):789–95.PubMedCrossRef

Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008;35(12):2320–33.PubMedCrossRef

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35(13):1773–82.PubMedCrossRef

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47.PubMedCrossRef

10.

Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol 2009;4:1.PubMedCrossRef

11.

http://clinicaltrials.gov/ct2/show/NCT00840749

12.

Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med 1998;25(9):1238–43.PubMedCrossRef

13.

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33(11):1972–80.PubMed

14.

van Baardwijk A, Bosmans G, Dekker A, van Kroonenburgh M, Boersma L, Wanders S, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol 2007;82(2):145–52.PubMedCrossRef

15.

Hautzel H, Müller-Gärtner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997;38(9):1384–6.PubMed

16.

Murayama M, Harada N, Kakiuchi T, Fukumoto D, Kamijo A, Kawaguchi AT, et al. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med 2009;50(2):290–5.PubMedCrossRef

17.

Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest 1998;114(4):1105–11.PubMedCrossRef

18.

Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, et al. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions. Ann Nucl Med 2009;23(5):427–35.PubMedCrossRef

19.

Sanz-Viedma S, Torigian DA, Parsons M, Basu S, Alavi A. Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging. Rev Esp Med Nucl 2009;28(3):159–66.PubMedCrossRef

Title: 18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study
Authors: Erwin M. Wiegman
Jan Pruim
Jan F. Ubbels
Harry J. M. Groen
Johannes A. Langendijk
Joachim Widder
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1706-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2011

In vivo positron emission tomography imaging with [11C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons

Feasibility of 62Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease

Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma

Synchronous malignancies in patients with squamous cell carcinomas of the oral cavity

Erratum to: Focus on time-of-flight PET: the benefits of improved time resolution

Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3 Tesla